Pulmonary damage after hospitalization for acute COVID-19, an exploratory prospective cohort study.
Completed
- Conditions
- COVID-19coronavirus1004743810037454
- Registration Number
- NL-OMON54891
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
1. Patients eligible for post-COVID-19 care program
2. Written informed consent from patient or legal representative
3. CT during admission with CO-RADS ><= 3 or Laboratory confirmed (PRC of
serologic) diagnosis of COVID-19
Exclusion Criteria
1. Age <18 years
2. Pregnancy
3. Subjects with a history of allergy or intolerance to iodinated intravenous
contrast media
4. Subjects with pre-existent severe renal impairment (creatinine clearance
less than 30 mL/min/1.73m^2)
5. Subjects using therapeutic anticoagulation
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary objective of the study is to determine types and prevalence of<br /><br>residual pulmonary damage after hospital admission for acute COVID-19 at 3 and<br /><br>12 months follow-up.</p><br>
- Secondary Outcome Measures
Name Time Method <p>1. To determine clinical and imaging parameters in the acute phase of COVID-19<br /><br>that may predict lung damage (including pulmonary perfusion abnormalities) at 3<br /><br>and 12 month follow-up<br /><br>2. To determine which types of damage remain after 1 year<br /><br>3. To correlate the amount and type of pulmonary damage with the clinical<br /><br>parameters 3 and 12 month follow-up<br /><br>4. To determine the value of d-dimer levels and YEARS criteria at 3 months for<br /><br>prediction of pulmonary perfusion abnormalities </p><br>